Products BMS-986369
BMS-986369 Phase 1/2 Recruiting ⚡ Active Relapsed or Refractory T-cell Lymphomas
Relapsed or Refractory T-cell Lymphomas
Nov 20, 2023 → Oct 10, 2030
About BMS-986369 BMS-986369 is a phase 1/2 stage product being developed by Bristol Myers Squibb for Relapsed or Refractory T-cell Lymphomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06035497. Target conditions include Relapsed or Refractory T-cell Lymphomas.
Clinical Trials (3) NCT ID Phase Status Start Completion Indication NCT06035497 Phase 1/2 Recruiting Nov 20, 2023 Oct 10, 2030 Relapsed or Refractory T-cell Lymphomas NCT05567510 Phase 1 Completed Oct 20, 2022 Dec 27, 2022 Healthy Participants NCT05350800 Phase 1 Completed Sep 12, 2022 May 4, 2023 Healthy Volunteer
Competing Products 20 competing products in Relapsed or Refractory T-cell Lymphomas
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3
Other Products from Bristol Myers Squibb